Challenges and solutions: The present and future of cell therapies for T1D
Breakthrough T1D is funding research that supports manufactured islet cell source, survival, and protection and is also driving initiatives to…
Medical Affairs: Closing the gap between access and adoption
Breakthrough T1D's new Medical Affairs unit will address the numerous challenges contributing to the slow adoption of groundbreaking T1D therapies.
Cell therapies 101: What are stem cells and why do they matter?
Researchers are harnessing the power of stem cells to generate functional beta cells and islets, driving us closer toward type…
Cell therapy first: transplanted islets working without immunosuppressives
Today, Sana Biotechnology released significant clinical data: the first person with type 1 diabetes (T1D) who received deceased donor islets…
2024 greatest T1D hits: A glance at this year’s achievements
While we look back on 2024, we can reflect upon the incredible progress we’ve made in advancing breakthroughs toward cures…
Vertex launches pivotal trial for stem-cell derived islet therapy
On Monday, Vertex made a monumental announcement. Their Phase 1/2 trial for VX-880 is converting to a Phase 1/2/3 pivotal…
Novel way to protect transplanted cells shows promise
A novel immune therapy called tegoprubart made by Eledon Pharmaceuticals and being tested in kidney transplant patients has the potential…
Stem Cell-Derived Islets Show Promise In Another Study
A new study published in Cell and summarized in Nature has shown positive results using stem cell-derived islets to restore…
Powering research breakthroughs
We invest in the most promising research to turn ideas into life-changing therapies and lead the way to cures.
A New Shot on Goal for Cell Therapies In T1D
Eledon Pharmaceuticals announces new funding from the T1D Fund and the launch of their clinical trial for tegoprubart in T1D.
